All KOL Pulse conferences
Post-Conference Intelligence · Sep 6 – Sep 9, 2025

WCLC / IASLC 2025

San Diego, CA — top KOL voices, trial buzz, and themes pulled from verified physician social.
198Physician tweets
46Unique KOLs
667.6KTotal impressions
KOL Voices

Who moved the needle at WCLC / IASLC 2025

Top physician voices ranked by impressions. Institutional / media accounts excluded.

Stephen V Liu, MD
Stephen V Liu, MD
@stephenvliu
94.1K imp · 18 tweets
 Hidehito HORINOUCHI
Hidehito HORINOUCHI
@hhorinouchi
61.4K imp · 13 tweets
 Patrick Forde
Patrick Forde
@fordepatrick
55.2K imp · 9 tweets
 Jarushka Naidoo
Jarushka Naidoo
@drjnaidoo
44.2K imp · 10 tweets
 Dr. Antonio Calles 🫁🚭
Dr. Antonio Calles 🫁🚭
@tony_calles
42.0K imp · 5 tweets
 Dr Amol Akhade
Dr Amol Akhade
@suyogcancer
41.6K imp · 5 tweets
 Drew Moghanaki
Drew Moghanaki
@drewmoghanaki
36.8K imp · 5 tweets
 Charu Aggarwal, MD, MPH, FASCO
Charu Aggarwal, MD, MPH,
@charuaggarwalmd
27.2K imp · 5 tweets
 Brendon Stiles
Brendon Stiles
@brendonstilesmd
24.0K imp · 4 tweets
 Bartomeu Massuti
Bartomeu Massuti
@bmassutis
23.0K imp · 10 tweets
 Dr. Estela Rodriguez
Dr. Estela Rodriguez
@latinamd
18.0K imp · 18 tweets
 Tejas Patil
Tejas Patil
@tejaspatilmd
16.9K imp · 8 tweets

Top trials discussed

FLAURA2 Osimertinib + Chemo · 1L EGFR NSCLC124.5K imp · 26 tweets→HARMONi Ivonescimab + Chemo · EGFRm NSCLC83.9K imp · 27 tweets→MARIPOSA Amivantamab + Lazertinib · 1L EGFR NSCLC53.3K imp · 8 tweets→KEYNOTE-671 Pembro · Perioperative NSCLC7.8K imp · 2 tweets→CheckMate 77T Nivolumab · Perioperative NSCLC418 imp · 1 tweets→
Emerging Themes

What KOLs were talking about

Click any theme to see the top tweets that matched.

Dr Amol Akhade
@suyogcancer
🚨 Trials to Watch – WCLC 2025 🚨 🔑 Plenary LBAs: FLAURA2: Osimertinib + Chemo (OS update) Aumolertinib + Chemo (EGFRm NSCLC) HARMONi-A: Ivonescimab + Chemo vs Chemo ARROS-1: Zidesamtinib (ROS1+) CheckMate 816: Neoadjuvant Nivolumab (OS) EA5181: Durvalumab + CRT in Stage III https://t.co/4WqpLoR96K
21.9K impressions
Stephen V Liu, MD
@stephenvliu
Dr. Jonathan Goldman presents the HARMONi data at #WCLC25. In EGFR NSCLC post TKI, adding ivonescimab (VEGF/PD1 bispecific) improves PFS (4.4 to 6.8m, HR 0.52). Numeric difference in OS in Western pts, but complicated analysis in heterogenous group. Improvement over MARIPOSA2? https://t.co/ZB0TVXi3Ze
21.4K impressions
Charu Aggarwal, MD, MPH, FASCO
@charuaggarwalmd
Awaited results of HARMONi trial evaluating ivonescimab, a PD1/VEGF bispecific presented by Dr. Jonathan Goldman presented @IASLC #WCLC25 🔹PFS HR 0.52 🔹OS immature How will this fit into a packed landscape of chemo, ADCs and amivantamab based therapy? It remains important to https://t.co/ohQVqtbG52
16.9K impressions
Benjamin Besse
@benjaminbessemd
EGFR update 7 potential options: •3rd gen TKI: osimertinib, lazertinib, aumolertinib •Amivantamab •Pemetrexed •Carboplatin •Ivonescimab •Dato-DXd OS data favor combos upfront—but real-world ≠ trial. In RWD, ~40% of newly diagnosed pts wouldn’t qualify for FLAURA2 #WCLC25 https://t.co/U08kwhQ5Yg
15.0K impressions
Dr Amol Akhade
@suyogcancer
Is this the end ? Or beginning? For ivonescimab. @Alfdoc2 @StephenVLiu @BalazsHalmosMD @RManochakian @OncBrothers @OncoAlert @chulkimMD @dr_yakupergun https://t.co/eqVdanRawk
7.1K impressions
Dr Amol Akhade
@suyogcancer
HARMONi-A and the Curious Case of OS: From “Negative Drift” to a Positive Surprise One of the most anticipated stories at #WCLC25 will be the HARMONi-A trial of ivonescimab (PD-1/VEGF bispecific) in EGFR-mutated, TKI-resistant NSCLC. Why? Because the overall survival (OS) curve https://t.co/R0RZ3PwFEg
7.0K impressions
Stephen V Liu, MD
@stephenvliu
Dr. Jonathan Goldman presents the HARMONi data at #WCLC25. In EGFR NSCLC post TKI, adding ivonescimab (VEGF/PD1 bispecific) improves PFS (4.4 to 6.8m, HR 0.52). Numeric difference in OS in Western pts, but complicated analysis in heterogenous group. Improvement over MARIPOSA2? https://t.co/ZB0TVXi3Ze
21.4K impressions
Charu Aggarwal, MD, MPH, FASCO
@charuaggarwalmd
Awaited results of HARMONi trial evaluating ivonescimab, a PD1/VEGF bispecific presented by Dr. Jonathan Goldman presented @IASLC #WCLC25 🔹PFS HR 0.52 🔹OS immature How will this fit into a packed landscape of chemo, ADCs and amivantamab based therapy? It remains important to https://t.co/ohQVqtbG52
16.9K impressions
Rami Manochakian MD, FASCO Can
@rmanochakian
🔥🚨@OncoAlert HOT OFF THE PRESS. Just published @TheLancetOncol In conjunction with presentation @IASLC #WCLC25 Impressive Results of: ⭐️#DeLLphi303: Phase 1b trial of: #Tarlatamab + anti-PD-L1 as #maintenance Tx after 1st line Chemo/IO in ES #SmallCe…
8.9K impressions
Dr Amol Akhade
@suyogcancer
HARMONi-A and the Curious Case of OS: From “Negative Drift” to a Positive Surprise One of the most anticipated stories at #WCLC25 will be the HARMONi-A trial of ivonescimab (PD-1/VEGF bispecific) in EGFR-mutated, TKI-resistant NSCLC. Why? Because the overall survival (OS) curve https://t.co/R0RZ3PwFEg
7.0K impressions
Patrick Forde
@fordepatrick
Great thread, proud of @Joshua_Reuss & many pt/colleagues in bringing to fruition this neoadjuvant immunotherapy trial for mesothelioma w cutting edge liquid biopsy data from @ValsamoA , now open access @NatureMedicine ! https://t.co/POwrWNbl1R @curemeso @cancertrials_ie #WCLC25 https://t.co/h…
4.7K impressions
Dr Amol Akhade
@suyogcancer
Data that we all were waiting for (ivonescimab + chemo post-osimertinib): HARMONi-A (WCLC25) – ivonescimab (PD-1/VEGF bispecific) + chemo vs chemo after 3rd-gen EGFR-TKI progression mPFS 6.8 vs 4.4 mo (HR 0.52, p<0.001) ORR 44.7% vs 34.2% Intracranial PFS benefit (HR 0.34 in BM
4.2K impressions
Hidehito HORINOUCHI
@hhorinouchi
☑️#WCLC25 #LCSM Mini Oral Abstract🆙 🔥Tumor Informed Whole Genome Based MRD for Predicting Recurrence in Early-Stage Resectable NSCLC 🎯Signatera by @NateraOncology 🎯MRD+ RFS (HR: 20, 95% CI: 1.8-230) 🎙️ Dr. Gaston Becharano @OncoAlert @Larvol @IASLC https://t.co/H2B64oYkKO https://t.co/hDMj…
7.8K impressions
Jarushka Naidoo
@drjnaidoo
#WCLC25 Presidential Superb FLAURA2 OS discussion by @danieltanmd, main questions: - combo may ⬆️likelihood of long-term response? - clinical/molec/ctDNA factors relevant - refinement needs complex integration of factors Extremely elegant slides, I plan to use 😃 @IASLC #LCSM https://t.co/MnW77GG8FV
7.6K impressions
Patrick Forde
@fordepatrick
Great thread, proud of @Joshua_Reuss & many pt/colleagues in bringing to fruition this neoadjuvant immunotherapy trial for mesothelioma w cutting edge liquid biopsy data from @ValsamoA , now open access @NatureMedicine ! https://t.co/POwrWNbl1R @curemeso @cancertrials_ie #WCLC25 https://t.co/h…
4.7K impressions
Hidehito HORINOUCHI
@hhorinouchi
☑️#WCLC25 #LCSM Mini Oral Abstract🆙 🔥Ultrasensitive MRD Improves Detection in Resectable Stage I NSCLC 🎯Preoperative ctDNA detection rates in p-stage IA and IB were 33% and 71%, respectively 🎙️ Dr. Natasha Leighl @OncoAlert @Larvol @IASLC https://t.co/H2B64oYSAm https://t.co/SKBWsEqExK
4.4K impressions
Shankar Siva
@_shankarsiva
#WCLC2025 #LCSM neoadura (neoadjuvant osimertinib) - MRD analysis suggests that ctDNA can be prognostic and predictive for outcome and path response in eGFR mutated #lungcancer? https://t.co/whoyQBvCy5
3.5K impressions
Charu Aggarwal, MD, MPH, FASCO
@charuaggarwalmd
CtDNA MRD presentation today from #NeoADAURA trial demonstrates that: 🔹 ultra sensitive assays can detect higher proportion of pts w/ MRD 🔹 as we know, these assays are prognostic at baseline 🔹 clearance correlates with MPR @IASLC #WCLC25 https://t.co/nE5IIfv94m
1.7K impressions
Hidehito HORINOUCHI
@hhorinouchi
☑️#WCLC25 #LCSM Mini Oral Abstract🆙 🔥Tumor Informed Whole Genome Based MRD for Predicting Recurrence in Early-Stage Resectable NSCLC 🎯Signatera by @NateraOncology 🎯MRD+ RFS (HR: 20, 95% CI: 1.8-230) 🎙️ Dr. Gaston Becharano @OncoAlert @Larvol @IASLC https://t.co/H2B64oYkKO https://t.co/hDMj…
7.8K impressions
Hidehito HORINOUCHI
@hhorinouchi
☑️#WCLC25 #LCSM Oral Abstract🆙 🔥NeoADAURA MRD Analysis 🎯NeXT Personal® @PersonalisInc 🌟71% were MRD+ / 30% COBAS-detected plasma EGFRm 🎯EFS (HR MRD - vs +, 0.24, 95% CI 0.07, 0.80) 🎙️ Dr. Collin M Blakely @OncoAlert @Larvol @IASLC #Liquidbiopsy https://t.co/upYlkSn4rN http…
5.0K impressions
Hidehito HORINOUCHI
@hhorinouchi
☑️#WCLC25 #LCSM Mini Oral Abstract🆙 🔥Ultrasensitive MRD Improves Detection in Resectable Stage I NSCLC 🎯Preoperative ctDNA detection rates in p-stage IA and IB were 33% and 71%, respectively 🎙️ Dr. Natasha Leighl @OncoAlert @Larvol @IASLC https://t.co/H2B64oYSAm https://t.co/SKBWsEqExK
4.4K impressions
Shankar Siva
@_shankarsiva
#WCLC2025 #LCSM neoadura (neoadjuvant osimertinib) - MRD analysis suggests that ctDNA can be prognostic and predictive for outcome and path response in eGFR mutated #lungcancer? https://t.co/whoyQBvCy5
3.5K impressions
Charu Aggarwal, MD, MPH, FASCO
@charuaggarwalmd
CtDNA MRD presentation today from #NeoADAURA trial demonstrates that: 🔹 ultra sensitive assays can detect higher proportion of pts w/ MRD 🔹 as we know, these assays are prognostic at baseline 🔹 clearance correlates with MPR @IASLC #WCLC25 https://t.co/nE5IIfv94m
1.7K impressions
Dr. Estela Rodriguez
@latinamd
#WCLC25 Day 3 Presidential Symposium Excellent discussion by Dr Tina Cascone @MDAndersonNews on #NADIMII results highlighting scientific rationale and gaps in understanding (role of MRD, understanding patterns of recurrence and escalation/ de-escalation strategies) #lcsm @IASLC https://t.co…
530 impressions
Clinical Trial Buzz

Trials discussed at WCLC / IASLC 2025

Ranked by total impressions. Click through to the full KOL Pulse trial profile.

FLAURA2 Osimertinib + Chemo · 1L EGFR NSCLC124.5K imp · 26 tweets→HARMONi Ivonescimab + Chemo · EGFRm NSCLC83.9K imp · 27 tweets→MARIPOSA Amivantamab + Lazertinib · 1L EGFR NSCLC53.3K imp · 8 tweets→KEYNOTE-671 Pembro · Perioperative NSCLC7.8K imp · 2 tweets→CheckMate 77T Nivolumab · Perioperative NSCLC418 imp · 1 tweets→
Top Tweets

The 10 tweets that defined WCLC / IASLC 2025

Physician voices only, ranked by impressions. Click any card to open the original on X.

Dr Amol Akhade
@suyogcancer
#1
🚨 Trials to Watch – WCLC 2025 🚨 🔑 Plenary LBAs: FLAURA2: Osimertinib + Chemo (OS update) Aumolertinib + Chemo (EGFRm NSCLC) HARMONi-A: Ivonescimab + Chemo vs Chemo ARROS-1: Zidesamtinib (ROS1+) CheckMate 816: Neoadjuvant Nivolumab (OS) EA5181: Durvalumab + CRT in Stage III https://t.co/4WqpLoR96K
21.9K impressions
Stephen V Liu, MD
@stephenvliu
#2
Dr. Jonathan Goldman presents the HARMONi data at #WCLC25. In EGFR NSCLC post TKI, adding ivonescimab (VEGF/PD1 bispecific) improves PFS (4.4 to 6.8m, HR 0.52). Numeric difference in OS in Western pts, but complicated analysis in heterogenous group. Improvement over MARIPOSA2? https://t.co/ZB0TVXi3Ze
21.4K impressions
Drew Moghanaki
@drewmoghanaki
#3
“Resectability depends on a state of mind” - @Mat_Guc …and society perspectives #WCLC25 https://t.co/fCOLCX5FDC
21.3K impressions
Dr. Antonio Calles 🫁🚭
@tony_calles
#4
💥 Just @NEJM published OS data from MARIOOSA vs presented FLAURA-2 data at @IASLC #WCLC25 Survival of intensification strategy in 1L EGFR lung cancer. Both works, different ⚠️side effects, and $$$$. Pick your winner. #LCSM 🥊 FLAURA-2 vs MARIPOSA https://t.co/bIrUTX9kab
20.8K impressions
Patrick Forde
@fordepatrick
#5
Surgical outcomes correlation with 5 year survival with neoadj chemo IO for lung cancer in CheckMate 816 presented by the legendary Prof. @t_mitsudomi #WCLC25 overall v good outcomes, remarkably so for pts with pneumonectomy #LCSM https://t.co/ywTKQdgwmf
19.4K impressions
Jarushka Naidoo
@drjnaidoo
#6
✨ Welcome to #WCLC25! ✨ From your Co-Chairs 🇮🇪🇨🇭🇮🇹🇪🇸may this week spark bold ideas, meaningful connections, and new horizons in lung cancer care Here’s to a week of science & collaboration, in every session @IASLC @NReguart @IsaOpitz @UmbertoMalapel1 @DrJNaidoo #LCSM https:…
19.4K impressions
Stephen V Liu, MD
@stephenvliu
#7
Dr. @dplanchard at #WCLC25 with highly anticipated Presidential Plenary presentation with OS results from FLAURA2: first line chemo + osimertinib improves OS from 37.6 to 47.5m, HR 0.77, 4y OS rate 41% to 49%. Benefit seen across subgroups. Strong results - similar to MARIPOSA. https://t.co/qYOP287NyK
19.1K impressions
Charu Aggarwal, MD, MPH, FASCO
@charuaggarwalmd
#8
Awaited results of HARMONi trial evaluating ivonescimab, a PD1/VEGF bispecific presented by Dr. Jonathan Goldman presented @IASLC #WCLC25 🔹PFS HR 0.52 🔹OS immature How will this fit into a packed landscape of chemo, ADCs and amivantamab based therapy? It remains important to https://t.co/ohQVqtbG52
16.9K impressions
Brendon Stiles
@brendonstilesmd
#9
Herculean effort EA5181 investigators - unfortunately confirmed no benefit w/ concurrent ICI w/ CRT for patients w/ stage III NSCLC. We need more innovative trials in this space- -induction chemo/ICI? -combo of novel agents post CRT? -individualized rx assignment? #WCLC25 https://t.co/Mpsa9fyGL1
15.8K impressions
Benjamin Besse
@benjaminbessemd
#10
EGFR update 7 potential options: •3rd gen TKI: osimertinib, lazertinib, aumolertinib •Amivantamab •Pemetrexed •Carboplatin •Ivonescimab •Dato-DXd OS data favor combos upfront—but real-world ≠ trial. In RWD, ~40% of newly diagnosed pts wouldn’t qualify for FLAURA2 #WCLC25 https://t.co/U08kwhQ5Yg
15.0K impressions
← Back to all conferences